EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sage Therapeutics's enterprise value is $103.57 Mil.
Sage Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-507.19 Mil. Therefore, Sage Therapeutics's EV-to-EBITDA for today is -0.20.
The historical rank and industry rank for Sage Therapeutics's EV-to-EBITDA or its related term are showing as below:
SAGE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -27.64 Med: -1.88 Max: 4.89
Current: -0.19
During the past 12 years, the highest EV-to-EBITDA of Sage Therapeutics was 4.89. The lowest was -27.64. And the median was -1.88.
SAGE's EV-to-EBITDA is ranked worse than 100% of 470
companies
in the Biotechnology industry
Industry Median: 9.14
vs SAGE: -0.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Sage Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Sage Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sage Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Sage Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sage Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sage Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sage Therapeutics's EV-to-EBITDA falls into.
Sage Therapeutics's current Enterprise Value is $103.57 Mil.
Sage Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-507.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sage Therapeutics's PE Ratio for today is calculated as:
Sage Therapeutics's share price for today is $13.63.
Sage Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Sage Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Sage Therapeutics (Sage Therapeutics) Business Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SAGE has been successfully added to your 